Primary Biliary Cholangitis Pipeline Analysis Report 2026

Report Coverage

The Primary Biliary Cholangitis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into primary biliary cholangitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for primary biliary cholangitis. The primary biliary cholangitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The primary biliary cholangitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with primary biliary cholangitis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to primary biliary cholangitis.

Read more about this report - Request a Free Sample

Primary Biliary Cholangitis Pipeline Outlook

Primary biliary cholangitis is a rare, chronic autoimmune liver disease characterized by progressive destruction of the small intrahepatic bile ducts. It occurs when immune-mediated inflammation impairs bile flow, leading to bile acid accumulation, cholestasis, ongoing liver injury, fibrosis, and, if untreated, eventual cirrhosis and liver failure.

Primary biliary cholangitis treatment focuses on slowing disease progression, improving cholestasis, and relieving symptoms. Ursodeoxycholic acid is first-line therapy, while newer agents target bile acid regulation and inflammatory pathways in patients with inadequate response. In August 2024, Gilead Sciences’ Livdelzi (seladelpar) received United States Food and Drug Administration accelerated approval as a primary biliary cholangitis pipeline therapy, demonstrating significant alkaline phosphatase reduction and pruritus improvement, positioning it as a promising option for patients with inadequate response or intolerance to ursodeoxycholic acid.

Primary Biliary Cholangitis Epidemiology

This analysis highlights key epidemiological insights shaping the pipeline. According to the primary biliary cholangitis epidemiology forecast by Expert Market Research, the global pooled prevalence is approximately 18.1 cases per 100,000 population, while the incidence is about 1.8 new cases per 100,000 person-years, indicating a gradually rising trend. Incidence increases significantly with age, particularly above 70 years. As per Zakary Warsop et al., 2024, prevalence in the United Kingdom ranges from 20 to 35 per 100,000, with a strong female predominance. These trends guide targeted therapeutic development.

Primary Biliary Cholangitis – Pipeline Therapeutic Assessment

Primary Biliary Cholangitis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II and III, at 39%, cover a major share of the total primary biliary cholangitis clinical trials, highlighting a strong mid- to late-stage development focus. Phase I accounts for 12%, while early phase I represents 7%. Overall, this phase distribution reflects a maturing and increasingly competitive primary biliary cholangitis pipeline with a clear emphasis on advancing clinically validated therapies.

Primary Biliary Cholangitis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the primary biliary cholangitis pipeline analysis include small molecules, monoclonal antibodies, and peptides. The primary biliary cholangitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for primary biliary cholangitis. Farnesoid X receptor agonists continue to represent a key drug class in the pipeline despite recent regulatory setbacks. For instance, obeticholic acid previously demonstrated disease-modifying potential by regulating bile acid synthesis. Additionally, next-generation bile acid modulators and non-steroidal farnesoid X receptor agonists are under evaluation to improve efficacy and safety outcomes.

Primary Biliary Cholangitis Clinical Trials – Key Players

The EMR report for the primary biliary cholangitis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed primary biliary cholangitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in primary biliary cholangitis clinical trials:

• COUR Pharmaceutical Development Company, Inc.
• Cascade Pharmaceuticals, Inc.
• Kowa Research Institute, Inc.
• Zydus Therapeutics Inc.
• Gilead Sciences
• Ipsen
• Tharimmune Inc.
• Mirum Pharmaceuticals, Inc.
• ChemomAb Ltd.
• CuromeBiosciences

Primary Biliary Cholangitis – Emerging Drugs Profile

Key Questions Answered in the Primary Biliary Cholangitis Pipeline Insight Report

• Which companies/institutions are leading the primary biliary cholangitis drug development?
• Which company is leading the primary biliary cholangitis pipeline development activities?
• What is the current primary biliary cholangitis commercial assessment?
• What are the opportunities and challenges present in the primary biliary cholangitis pipeline landscape?
• What is the efficacy and safety profile of primary biliary cholangitis pipeline drugs?
• Which company is conducting major trials for primary biliary cholangitis drugs?
• Which companies/institutions are involved in primary biliary cholangitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in primary biliary cholangitis?

Reasons To Buy This Report

The Primary Biliary Cholangitis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for primary biliary cholangitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into primary biliary cholangitis collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Primary Biliary Cholangitis (PBC) Epidemiology Forecast

Primary Biliary Cholangitis Therapeutics Market